RV7.F
Halozyme Therapeutics, Inc.
FrankfurtEUREQUITY
Healthcare
DELAYED
Last price
92.90
▲ 0.92 (1.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
92.20
Prev close
91.98
Day high
93.36
Day low
92.20
Volume
1.05K
Market cap
$10.54B
P/E (TTM)
31.82
52W range
52.50 – 93.36
Day trading desk
Gap from prior close
+0.24%
Prior close 91.98
VWAP
93.14
-0.25% from price
Relative volume
13.13×
Unusually busy
Session range
1.26%
92.20 – 93.36
Position in range
60%
Mid range
ATR (14D)
2.94
3.17% of price
Prior day high
92.60
PDH
Prior day low
89.30
PDL
Bid / ask spread
—
Quote not published
Session volume
1.05K
Avg 80
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+4.38%
+5.6%
1M
+28.60%
+25.3%
3M
+58.05%
+55.7%
6M
+54.99%
+43.2%
YTD
+59.46%
+47.6%
1Y
+51.65%
+31.6%
3Y
+135.31%
+60.4%
5Y
+166.27%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on RV7.F open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.26M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 19, 26 | TORLEY HELEN I Chief Executive Officer |
SELL | 60.00K | $6.28M | Direct |
| Aug 19, 26 | TORLEY HELEN I Chief Executive Officer |
CONVERSION | 60.00K | $1.10M | Direct |
| Aug 10, 26 | CONNAUGHTON BERNADETTE M. Director |
SELL | 1.63K | $167.15K | Direct |
| Jul 8, 26 | TORLEY HELEN I Chief Executive Officer |
SELL | 1.92K | $153.39K | Direct |
| Jul 8, 26 | TORLEY HELEN I Chief Executive Officer |
CONVERSION | 1.92K | $23.21K | Direct |
| Jul 1, 26 | CONNAUGHTON BERNADETTE M. Director |
SELL | 1.63K | $124.65K | Direct |
| Jun 29, 26 | KRISHNAN MAHESH M.D., MPH Director |
SELL | 7.30K | $547.80K | Direct |
| Jun 29, 26 | KRISHNAN MAHESH M.D., MPH Director |
CONVERSION | 7.30K | $280.91K | Direct |
| Jun 12, 26 | SNYDER MARK HOWARD Officer |
— | 5.03K | — | Direct |
| Jun 3, 26 | TORLEY HELEN I Chief Executive Officer |
SELL | 50.00K | $3.37M | Direct |
| Jun 3, 26 | TORLEY HELEN I Chief Executive Officer |
CONVERSION | 50.00K | $603.50K | Direct |
| Jun 1, 26 | CONNAUGHTON BERNADETTE M. Director |
SELL | 1.63K | $107.59K | Direct |
| May 13, 26 | TORLEY HELEN I Chief Executive Officer |
SELL | 50.00K | $3.43M | Direct |
| May 13, 26 | TORLEY HELEN I Chief Executive Officer |
CONVERSION | 50.00K | $603.50K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CONNAUGHTON BERNADETTE M. |
Director | 40.42K | Sale |
DUNCAN BARBARA GAYLE |
Director | 23.71K | Stock Award(Grant) |
HENDERSON JEFFREY WILLIAM |
Director | 36.57K | Stock Award(Grant) |
LABARRE MICHAEL J. |
Chief Technology Officer | 173.76K | Sale |
LABROSSE NICOLE |
Chief Financial Officer | 38.49K | Conversion of Exercise of derivative security |
MATSUI CONNIE L |
Director | 183.03K | Stock Gift |
MIYASHITA AKIKO MONI |
Director | 24.94K | Stock Award(Grant) |
POSARD MATTHEW L |
Director | 77.83K | Stock Award(Grant) |
SNYDER MARK HOWARD |
Officer | 49.93K | Conversion of Exercise of derivative security |
TORLEY HELEN I |
Chief Executive Officer | 767.78K | Sale |
Fundamentals
Market cap$10.54B
Enterprise value$12.39B
Revenue (TTM)$1.66B
Gross profit$1.27B
EBITDA$1.05B
Net income$413.60M
EPS (TTM)$2.92
Free cash flow$337.31M
Total cash$231.00M
Total debt$2.18B
Book value / share$1.09
Shares outstanding113.50M
Float112.17M
Short % of float—
Dividend yield—
Beta (5Y)0.85
Valuation & profitability ratios
Trailing P/E31.82
Forward P/E35.46
PEG ratio—
Price / sales—
Price / book85.29
EV / revenue7.45
EV / EBITDA11.79
Gross margin76.27%
Operating margin59.80%
Profit margin24.86%
Return on equity173.67%
Return on assets25.49%
Debt / equity1,517.69
Current ratio2.71
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.40B | $1.02B | $829.25M | $660.12M | +37.6% |
| Operating revenue | $1.40B | $1.02B | $829.25M | $660.12M | +37.6% |
| Cost of revenue | $228.77M | $159.42M | $192.36M | $139.30M | +43.5% |
| Gross profit | $1.17B | $855.91M | $636.89M | $520.81M | +36.4% |
| Research & development | $81.49M | $79.05M | $76.36M | $66.61M | +3.1% |
| Selling, general & admin | $207.09M | $154.34M | $149.18M | $143.53M | +34.2% |
| Total operating expense | $365.24M | $304.43M | $299.32M | $253.28M | +20.0% |
| Operating income | $802.59M | $551.48M | $337.57M | $267.53M | +45.5% |
| Net interest income | -$18.13M | -$18.09M | -$18.76M | -$16.95M | -0.2% |
| Pre-tax income | $466.88M | $557.13M | $348.33M | $248.92M | -16.2% |
| Tax provision | $149.99M | $113.04M | $66.73M | $46.79M | +32.7% |
| Net income | $316.89M | $444.09M | $281.59M | $202.13M | -28.6% |
| Net income to common | $316.89M | $444.09M | $281.59M | $202.13M | -28.6% |
| Basic EPS | 2.64 | 3.50 | 2.13 | 1.48 | -24.6% |
| Diluted EPS | 2.56 | 3.43 | 2.10 | 1.44 | -25.4% |
| EBIT | $485.00M | $575.23M | $367.09M | $265.87M | -15.7% |
| EBITDA | $573.05M | $656.54M | $451.95M | $315.51M | -12.7% |
| Basic shares | 119.84M | 126.83M | 131.93M | 136.84M | -5.5% |
| Diluted shares | 123.90M | 129.42M | 134.20M | 140.61M | -4.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $133.82M | $115.85M | $118.37M | $234.19M | — | +15.5% |
| Cash & short-term investments | $142.82M | $596.07M | $336.00M | $362.79M | — | -76.0% |
| Accounts receivable | $434.27M | $296.94M | $240.00M | $188.88M | — | +46.2% |
| Inventory | $176.47M | $141.86M | $127.60M | $100.12M | — | +24.4% |
| Total current assets | $825.21M | $1.09B | $746.42M | $739.01M | — | -24.0% |
| Property, plant & equipment | $82.14M | $75.03M | $74.94M | $75.57M | — | +9.5% |
| Goodwill & intangibles | $1.56B | $818.65M | $889.70M | $955.70M | — | +90.8% |
| Total assets | $2.53B | $2.06B | $1.73B | $1.84B | — | +22.4% |
| Total current liabilities | $177.09M | $139.10M | $112.49M | $130.79M | — | +27.3% |
| Current debt | — | — | — | $13.33M | $89.42M | — |
| Long-term debt | $2.14B | $1.51B | $1.50B | $1.49B | — | +42.3% |
| Total debt | $2.14B | $1.51B | $1.50B | $1.51B | — | +42.3% |
| Total liabilities | $2.48B | $1.70B | $1.65B | $1.67B | — | +45.7% |
| Retained earnings | $54.79M | $359.87M | $90.55M | $143.22M | — | -84.8% |
| Shareholder equity | $48.81M | $363.82M | $83.81M | $169.80M | — | -86.6% |
| Working capital | $648.12M | $946.24M | $633.93M | $608.22M | — | -31.5% |
| Net tangible assets | -$1.51B | -$454.83M | -$805.89M | -$785.90M | — | -232.7% |
| Shares issued | 117.78M | 123.14M | 126.77M | 135.15M | — | -4.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $316.89M | $444.09M | $281.59M | $202.13M | -28.6% |
| Depreciation & amortisation | $88.05M | $81.31M | $84.86M | $49.64M | +8.3% |
| Stock-based compensation | $51.56M | $43.38M | $36.62M | $24.40M | +18.9% |
| Change in working capital | -$152.26M | -$89.28M | -$38.67M | -$85.95M | -70.5% |
| Operating cash flow | $651.56M | $479.06M | $388.57M | $240.11M | +36.0% |
| Capital expenditure | -$294.74M | -$10.70M | -$15.29M | -$4.81M | -2,655.6% |
| Investing cash flow | -$545.81M | -$262.72M | -$96.91M | -$487.00M | -107.8% |
| Share buybacks | -$342.37M | -$250.00M | -$402.38M | -$200.00M | -36.9% |
| Financing cash flow | -$85.17M | -$218.86M | -$407.99M | $362.37M | +61.1% |
| Free cash flow | $356.82M | $468.37M | $373.28M | $235.30M | -23.8% |
| End cash position | $136.42M | $115.85M | $118.37M | $234.69M | +17.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $481.00M | $376.71M | $451.77M | $354.26M | $325.72M | — | +27.7% |
| Operating revenue | $481.00M | $376.71M | $451.77M | $354.26M | $325.72M | — | +27.7% |
| Cost of revenue | $79.17M | $79.24M | $78.77M | $55.24M | $46.36M | — | -0.1% |
| Gross profit | $401.83M | $297.47M | $373.00M | $299.02M | $279.36M | — | +35.1% |
| Research & development | $27.66M | $25.56M | $31.90M | $17.25M | $17.54M | — | +8.2% |
| Selling, general & admin | $57.00M | $57.88M | $77.03M | $46.09M | $41.61M | — | -1.5% |
| Total operating expense | $114.17M | $112.95M | $132.30M | $81.10M | $76.92M | — | +1.1% |
| Operating income | $287.65M | $184.52M | $240.70M | $217.92M | $202.44M | — | +55.9% |
| Net interest income | -$5.59M | -$5.51M | -$4.91M | -$4.30M | -$4.39M | — | -1.5% |
| Pre-tax income | $284.90M | $180.33M | -$100.85M | $218.96M | $204.94M | — | +58.0% |
| Tax provision | $54.99M | $30.28M | $40.74M | $43.73M | $39.78M | — | +81.6% |
| Net income | $229.91M | $150.05M | -$141.59M | $175.22M | $165.16M | — | +53.2% |
| Net income to common | $229.91M | $150.05M | -$141.59M | $175.22M | $165.16M | — | +53.2% |
| Basic EPS | 1.96 | 1.27 | -1.20 | — | 1.36 | 0.96 | +54.3% |
| Diluted EPS | 1.90 | 1.22 | -1.20 | — | 1.33 | 0.93 | +55.7% |
| EBIT | $290.49M | $185.84M | -$95.94M | $223.25M | $209.33M | — | +56.3% |
| EBITDA | $324.46M | $219.57M | -$69.26M | $243.67M | $229.83M | — | +47.8% |
| Basic shares | 117.27M | 118.14M | 117.67M | — | 121.34M | 123.22M | -0.7% |
| Diluted shares | 121.22M | 122.88M | 117.67M | — | 124.16M | 126.64M | -1.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $163.14M | $309.75M | $133.82M | $419.67M | $61.86M | -47.3% |
| Cash & short-term investments | $231.00M | $318.62M | $142.82M | $701.96M | $548.18M | -27.5% |
| Accounts receivable | $461.99M | $468.25M | $434.27M | $351.34M | $322.44M | -1.3% |
| Inventory | $137.13M | $155.47M | $176.47M | $185.80M | $181.50M | -11.8% |
| Total current assets | $933.02M | $1.00B | $825.21M | $1.33B | $1.12B | -7.0% |
| Property, plant & equipment | $84.27M | $82.23M | $82.14M | $71.42M | $71.52M | +2.5% |
| Goodwill & intangibles | $1.50B | $1.53B | $1.56B | $765.37M | $783.13M | -2.0% |
| Total assets | $2.58B | $2.67B | $2.53B | $2.22B | $2.05B | -3.6% |
| Total current liabilities | $344.44M | $363.21M | $177.09M | $837.23M | $134.28M | -5.2% |
| Current debt | $208.97M | $208.74M | — | $710.68M | — | +0.1% |
| Long-term debt | $1.94B | $1.94B | $2.14B | $800.07M | $1.51B | +0.1% |
| Total debt | $2.15B | $2.14B | $2.14B | $1.51B | $1.51B | +0.1% |
| Total liabilities | $2.43B | $2.45B | $2.48B | $1.72B | $1.72B | -0.8% |
| Retained earnings | $151.26M | $204.84M | $54.79M | $502.15M | $361.03M | -26.2% |
| Shareholder equity | $143.54M | $219.64M | $48.81M | $503.92M | $332.75M | -34.6% |
| Working capital | $588.59M | $639.83M | $648.12M | $491.52M | $988.39M | -8.0% |
| Net tangible assets | -$1.36B | -$1.31B | -$1.51B | -$261.45M | -$450.38M | -3.5% |
| Shares issued | 118.61M | 118.52M | 117.78M | 117.52M | 117.62M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $229.91M | $150.05M | -$141.59M | $175.22M | $165.16M | — | +53.2% |
| Depreciation & amortisation | $33.97M | $33.73M | $26.68M | $20.42M | $20.50M | — | +0.7% |
| Stock-based compensation | $17.70M | $16.64M | $16.57M | $12.16M | $12.16M | — | +6.4% |
| Change in working capital | -$43.56M | -$26.20M | -$9.43M | -$58.28M | -$92.02M | — | -66.3% |
| Operating cash flow | $240.89M | $180.08M | $219.03M | $178.60M | $99.71M | — | +33.8% |
| Capital expenditure | -$4.17M | -$3.74M | -$289.20M | -$3.03M | -$1.56M | — | -11.5% |
| Investing cash flow | -$62.66M | -$2.88M | -$741.79M | $201.61M | $84.79M | — | -2,078.1% |
| Share buybacks | — | — | $0 | -$38.88M | — | -$250.00M | — |
| Financing cash flow | -$326.25M | -$1.61M | $239.51M | -$22.40M | -$298.97M | — | -20,126.3% |
| Free cash flow | $236.72M | $176.34M | -$70.17M | $175.57M | $98.15M | — | +34.2% |
| End cash position | $163.99M | $312.01M | $136.42M | $419.67M | $61.86M | — | -47.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $484.32M | +36.7% |
| Next quarter | — | — | $537.86M | +19.1% |
| Current year | — | — | $1.85B | +32.7% |
| Next year | — | — | $2.05B | +10.6% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders1.11%
Held by institutions112.35%
Institutions holding902
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
89.81
+3.44% from price
SMA 20
82.55
+12.54% from price
SMA 50
72.71
+27.77% from price
SMA 100
65.33
+42.21% from price
SMA 200
62.33
+49.05% from price
EMA 12
87.83
+5.77% from price
EMA 26
81.75
+13.64% from price
EMA 50
75.44
+23.15% from price
RSI (14)
76.4
Overbought
MACD (12,26,9)
6.09
Hist 0.57
ATR (14)
2.94
3.17% of price
Realised vol 30D
64.6%
Annualised
Bollinger upper
99.86
20, 2σ
Bollinger lower
65.24
20, 2σ
50 / 200 cross
Golden
72.71 vs 62.33
Trend bias
Above 200
+49.05%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.04
Less volatile than market
Correlation to SPY
0.01
Largely independent
Realised vol 30D
64.6%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-22.4%
Peak to trough
Max drawdown 5Y
-50.9%
Peak to trough
ATR 14
2.94
3.17% of price
Beta (reported)
0.85
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 8, 26 | Leerink Partners | UPGRADE | Market Perform | Outperform |
| Aug 7, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 7, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Aug 7, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Aug 7, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 21, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 12, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Apr 29, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 19, 26 | Benchmark | MAINTAINED | Buy | Buy |
| Feb 19, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Jan 8, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Dec 19, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Headlines
IHCL to merge Oriental Hotels under proposed share-swap deal
Hotel Management Network · 4m ago
Houlihan Lokey (HLI): Buy, Sell, or Hold Post Q2 Earnings?
StockStory · 6m ago
LIVE: US unveils new sanctions on Iran
Yahoo Finance Video · 6m ago
CPK chooses T-ROC Global to deploy automated food kiosks
Verdict Food Service · 8m ago
Dunkin’ and BARK Unleash First-Ever Doggie Drive-Thru
QSR · 10m ago
XPENG Reports Q2 2026 Results: Gross Margin Reaches 20.7%, Overseas Market Drives 25% of H1 Revenue
PR Newswire · 10m ago
Cut Flowers Market Size to Reach $52.78 Billion by 2031 as Online Ordering and Cold-Chain Innovation Reshape Global Trade, Reports Mordor Intelligence
PR Newswire · 11m ago
Visy launches automated labelling system for fresh produce packs
Packaging Gateway · 12m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.